Furthermore, increased C5a levels have been reported in the plasma of non-small cell lung cancer (NSCLC) patients when compared to healthy controls, suggesting that local activation of complement is followed by systemic diffusion [91]. Here, C5 is linked to non-small cell lung carcinoma.